• Explore /
  • Poster
  • / Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors.

Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors.

Abstract Poster

Authors

null

James J. Harding

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

James J. Harding , Melinda L. Telli , Pamela N. Munster , Mai H. Le , Christopher Molineaux , Mark K. Bennett , Erik Mittra , Howard A. Burris III, Amy Sanders Clark , Mark Dunphy , Funda Meric-Bernstam , Manish R. Patel , Angela DeMichele , Jeffrey R. Infante

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Cytotoxic and Other Novel Agents

Clinical Trial Registration Number

NCT02071862

Citation

J Clin Oncol 33, 2015 (suppl; abstr 2512)

DOI

10.1200/jco.2015.33.15_suppl.2512

Abstract #

2512

Poster Bd #

228

Abstract Disclosures

Similar Posters

First Author: Angela DeMichele

First Author: Stefan K. Barta

First Author: Alexander I. Spira

First Author: Meredith Pelster